BRIEF—Seqirus joins global flu vaccine initiative

The Human Vaccines Project (HVP) announced on June 27 that Seqirus, a global leader in influenza, had joined the project's Universal Influenza Vaccine Initiative (UIVI).

Seqirus, a subsidiary of od Australia's CSL Limited, has been fighting flu for more than a century with innovative technology that helps vaccines into the hands of more patients.

"With a heritage dating back to the influenza pandemic of 1918, Seqirus is pleased to bring its expertise to the project, working alongside the eminent research organizations already involved," said Russell Basser, senior vice president of research and development at Seqirus.

The UIVI was launched late in 2017, and is a collaboration of leading anti-flu players in the quest against pandemics and seasonal outbreaks of the viral disease.

HVP chief executive Wayne Koff said: "We are pleased to collaborate with Seqirus, a leading innovator in influenza vaccines, as we expand our partnership with global stakeholders to accelerate the development of a more broadly protective influenza vaccine."